Shire plc (LSE: SHP, Nasdaq: SHPG) is buying Sarcode Bioscience Inc., a biopharmaceutical company.

Brisbane, Calif.-based Sarcode develops Lifitegrast, a medication that would help with symptoms of dry eye disease. Shire anticipates launching the medication in the U.S. as early as 2016.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.